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H istidine-rich glycoprotein (HRG),  first isolated as histidine-rich 3.8S α2-glycoprotein in 1972 
[1 , 2],  is a 75 kDa plasma glycoprotein mainly pro-
duced by the liver at approximately 100-150 μg/ml in 
human blood [3 , 4].  It is composed of 4 domains: cys-
tatin-like domain 1; cystatin-like domain 2; histidine- 
proline rich domain,  which has a unique 12 GHHPH 
tandem repeat amino acid sequence; and a C-terminal 
domain [5 , 6].  HRG is present in the blood of verte-
brates such as humans,  rats,  mice,  rabbits,  and chick-
ens,  and a few invertebrates [3 , 6 , 7].  HRG can bind a 
variety of ligands such as heparin,  factor XII (FXII),  
fibrinogen,  thrombospondin,  plasminogen,  C1q,  IgG,  
heme,  and lipopolysaccharide (LPS),  and can interact 
with dead cells,  bacteria,  and fungi.  These binding 
properties indicate that HRG modulates coagulation 
[8-14] and fibrinolysis [15-18],  helps to scavenge toxic 
substances [19-25] and dead cells [26-28],  and kills 
pathogens [29-32].  In addition,  our recent studies have 
reported that the plasma concentration of HRG was 
strikingly reduced during severe systemic inflammatory 
and septic condition triggered by infection,  leading to 
immunothrombosis and tissue damage,  and subse-
quent disseminated intravascular coagulation (DIC) and 
multiple organ failure (MOF) (Fig. 1) [33-40].  These 
results suggest that HRG is involved in the regulation of 
coagulation and fibrinolysis and the immune system in 
septic condition.  This review is focused on the function 
of HRG in these systems.
Functions of HRG in Coagulation and 
Fibrinolysis
Coagulation and fibrinolysis are rigorously regulated 
by several biological substances to prevent blood loss 
and unnecessary thrombus formation.  HRG is reported 
to bind to coagulation and fibrinolysis-related mole-
cules such as heparin,  FXII,  fibrinogen,  thrombos-
pondin,  and plasminogen [8-18].
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Heparin. The anti-coagulant activity of anti- 
thrombin III (ATIII) is enhanced in the presence of 
heparin.  HRG binds to heparin with high affinity,  
blocking the interaction between heparin and ATIII,  
and inhibiting its anti-coagulant activity [8-10].
FXII. HRG also modulates the intrinsic pathway 
through high-affinity binding to FXII,  inhibiting FXII 
autoactivation and FXIIa-mediated activation of FXI 
[11].
Fibrinogen and thrombospondin. Although HRG 
interaction with fibrinogen,  the platelet-bridging mole-
cule,  and subsequent incorporation into a fibrin clot 
does not induce the conversion of fibrinogen to fibrin 
within the clot,  this interaction influences the structure 
of the fibrin gel [12].  HRG inhibits the interaction 
between GPIIb/IIIa and fibrinogen via its histidine-rich 
domain in a Zn2+-dependent manner and inactivates the 
platelet-aggregation promoter thrombospondin on the 
surface of platelets,  thereby interfering with plate-
let-platelet interactions [13, 14].
Plasminogen. HRG inhibits the interaction of 
plasminogen with fibrin/fibrinogen and retards fibrino-
lysis due to its binding to the plasminogen lysine-bind-
ing site competing with fibrin binding [15].  Contrarily,  
immobilized HRG on cell surface heparan sulfate results 
in 30-fold increase in the conversion of plasminogen to 
plasmin by the fibrinolysis promoter tPA [16-18].
Immunothrombosis. Immunothrombosis is a key 
phenomenon in the development of septic pathogene-
sis,  which is triggered by activated-neutrophil adhesion 
to vascular endothelial cells,  and subsequent platelet 
accumulation and fibrin polymer deposition on their 
surface.  Immunothrombosis helps prevent the diffusion 
of pathogens to the systemic blood stream and their 
disposal in physiological conditions.  However,  impair-
ment of this regulation in sepsis causes immunothrom-
bus formation to lead to DIC and subsequent MOF [37-
40].  Our recent study revealed that HRG inhibits 
immunothrombus formation by keeping circulating 
neutrophils quiescent (Fig. 1) [35 , 36].
Functions of HRG in Immunity and 
Inflammation
Insoluble immune complexes (IICs). Although 
immune complexes promote the clearance of pathogens 
and foreign substances,  when IICs form and deposit in 
several organs,  they lead to tissue injury and inflamma-
tion.  C1q enhances IIC formation by directly binding 
and inducing the cross-linking of IgG molecules [19].  
The N-terminal domain of HRG binds to C1q and the 
F(ab) region of IgG,  inhibiting the formation of IICs 
composed of ovalbumin and the anti-ovalbumin anti-
body [20].  This domain binding also inhibits IIC for-
mation by preventing Fc-Fc interactions by masking 
IgG epitopes recognized by rheumatoid factor.  
Furthermore,  HRG promotes the solubilization and 
clearance of IICs [21].
Heme and LPS. Heme and LPS are damage-asso-
ciated molecular pattern (DAMP)/pathogen-associated 
molecular pattern (PAMP) molecules,  respectively,  that 
promote tissue injury.  HRG binds heme,  neutralizing 
heme cytotoxicity and inhibiting hemolysis [22-24].  
Synthetic peptides derived from the histidine-rich 
domain of HRG also bind and neutralize LPS,  inhibit-
ing LPS-stimulated IL-8 production of CD14-
transfected THP-1 cells [25].
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Fig. 1　 Scheme of septic pathogenesis.  DIC,  disseminated intravascular coagulation; MOF,  multiple organ failure.
Dying and dead cells. Rapid removal of apoptotic 
and necrotic cells from blood stream and tissue by 
phagocytes is necessary to maintain tissue homeostasis.  
Impairing clearance of these cells leads to the release of 
DAMP molecules,  which induce inflammation and 
tissue damage.  HRG can aid in the phagocytosis of 
apoptotic cells by macrophages,  by acting as a bridge 
between FcγRI on macrophages and DNA on the sur-
face of apoptotic cells [26].  Additionally,  HRG recog-
nizes intracellular phospholipids exposed in necrotic 
cells and aids in the recruitment of IgG,  leading to the 
phagocytosis of necrotic cells via FcγRI and heparan 
sulfate on phagocytes [27 , 28].
Antimicrobial activity. Moreover,  HRG exerts 
antimicrobial activity by binding to the surface of the 
Gram-positive bacteria Enterococcus faecalis and 
Streptococcus pyogenes,  the Gram-negative bacteria 
Escherichia coli,  and the fungus Candida albicans under 
acidic conditions or in the presence of Zn2+ and induc-
ing membrane destabilization [29-32].
Concluding Remarks
Septic pathogenesis can result from systemic coagu-
lation,  fibrinolysis,  and inflammation.  This review 
revealed that HRG can ameliorate septic condition by 
modulating these biological reactions through high-af-
finity binding to several key molecules and cells (Fig. 1).  
Thus,  HRG has potential value as a therapeutic drug for 
the treatment of sepsis.
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